Terumo Aortic Announces Commercial Launch of TREO Abdominal Stent Graft System in the United States

Following approval this year by the US Food and Drug Administration (FDA) of the TREO™ Abdominal Aortic Stent-Graft System for the treatment of patients with abdominal aortic aneurysms (AAA), Terumo Aortic announced today the commercial launch of this endovascular device.

One of the first procedures was undertaken by Matt Eagleton MD, Chief of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, US. Dr Eagleton commented, "The procedure was very successful, and the patient is recovering well. As the National Principal Investigator of the IDE study, I was impressed with the performance of the TREO stent-graft system. Stent migration and endoleaks are major concerns in EVAR and as the TREO device offers both suprarenal and infrarenal fixation, distributing the stent-graft fixation in two different anatomical levels, this may work to reduce potential migration as evidenced in the pivotal study. Furthermore, the device design leads to clinically meaningful aneurysm sac shrinkage."

Paul Kuznik, President of Terumo Aortic North America added, "This commercial implant represents a significant milestone for the company as we embark upon delivering the most comprehensive device portfolio within the aortic space."

TREO received CE Mark approval in 2015 and is integral to Terumo Aortic's market-leading portfolio of surgical, endovascular and hybrid devices to treat every segment of the aorta.